Abstract:Aggregates are recognized as one of the most critical product-related impurities in monoclonal antibody (mAb)-based therapeutics due to their negative impact on the stability and safety of the drugs. So far, investigational efforts have primarily focused on understanding the causes and effects of mAb self-aggregation, including both internal and external factors. In this study, we focused on understanding mAb stability in the presence of its monovalent fragment, formed through hinge cleavage and loss of one Fab unit (referred to as "Fab/c"), a commonly observed impurity during manufacturing and stability. The Fab/c fragments were generated using a limited IgdE digestion that specifically cleaves above the IgG1 mAb hinge region, followed by hydrophobic interaction chromatographic (HIC) enrichment. Two IgG1 mAbs containing different levels of Fab/c fragments were incubated under thermally accelerated conditions. A method based on size exclusion chromatography coupled with native mass spectrometry (SEC-UV-native MS) was developed and used to characterize the stability samples and identified the formation of heterogeneous dimers, including intact dimer, mAb-Fab/c dimer, Fab/c-Fab/c dimer, and mAb-Fab dimer. Quantitative analyses on the aggregation kinetics suggested that the impact of Fab/c fragment on the aggregation rate of individual dimer differs between a glycosylated mAb (mAb1) and a non-glycosylated mAb (mAb2). An additional study of deglycosylated mAb1 under 25°C accelerated stability conditions suggests no significant impact of the N-glycan on mAb1 total aggregation rate. This study also highlighted the power of SEC-UV-native MS method in the characterization of mAb samples with regard to separating, identifying, and quantifying mAb aggregates and fragments.

What problem does this paper attempt to address?

The problem that this paper attempts to solve is: **The influence of monoclonal antibody (mAb) fragments on the aggregation behavior of their intact molecules**, especially in the presence of monovalent fragments (Fab/c). Specifically, the study focused on how Fab/c fragments affect the stability of monoclonal antibodies and the formation rates of different dimers (such as intact dimers, mAb - Fab/c dimers, Fab/c - Fab/c dimers, etc.). ### Research Background and Problem Statement 1. **The importance of monoclonal antibody (mAb) aggregation**: - mAb aggregation is considered one of the most critical product - related impurities in monoclonal antibody therapeutics because they can reduce the stability and safety of the drug. - Aggregation may affect the biological efficacy of the drug and trigger adverse immune reactions, so it is necessary to deeply understand and monitor the aggregation behavior of mAb. 2. **Limitations of existing research**: - Current research mainly focuses on understanding the causes and effects of mAb self - aggregation, including internal and external factors. - The specific influence of mAb fragments (such as Fab/c) on mAb aggregation has not been studied in - depth. 3. **Research objectives**: - Evaluate the influence of Fab/c fragments on mAb aggregation behavior by means of size - exclusion chromatography (SEC) combined with native mass spectrometry (native MS). - Study the differences in aggregation kinetics of different mAbs (such as glycosylated and non - glycosylated mAbs) in the presence of Fab/c fragments. - Explore the influence of N - glycosylation on the total aggregation rate of mAb. ### Main Research Contents 1. **Experimental design**: - Generate Fab/c fragments using limited IgdE enzyme digestion and enrich these fragments by hydrophobic interaction chromatography (HIC). - Incubate two IgG1 mAbs (mAb1 and mAb2) containing different levels of Fab/c fragments under heat - accelerated conditions and analyze their stability changes. 2. **Analysis methods**: - Develop a method based on SEC - UV - native MS for separating, identifying and quantifying aggregates and fragments in mAb samples. - Compare the aggregation behaviors of different mAbs in the presence of Fab/c fragments by quantitatively analyzing the aggregation kinetics. 3. **Results and discussion**: - It was found that the presence of Fab/c fragments led to the formation of multiple heterodimers, including mAb - Fab/c, Fab/c - Fab/c and mAb - Fab dimers. - The aggregation rates of different mAbs (such as glycosylated mAb1 and non - glycosylated mAb2) in the presence of Fab/c fragments are different. - Further research shows that N - glycosylation has no significant influence on the total aggregation rate of mAb1. ### Conclusion This study reveals the specific influence of Fab/c fragments on mAb aggregation behavior and emphasizes the powerful ability of the SEC - UV - native MS method in characterizing mAb aggregation and fragments. This research provides important scientific basis for optimizing the manufacturing and stability of mAb drugs.

Evaluation of the impact of antibody fragments on aggregation of intact molecules via size exclusion chromatography coupled with native mass spectrometry

Evaluating Antibody Monomer Separation from Associated Aggregates Using Mixed-Mode Chromatography

Enhanced Thermal Stability and Reduced Aggregation in an Antibody Fab Fragment at Elevated Concentrations.

Investigation of monoclonal antibody dimers in a final formulated drug by separation techniques coupled to native mass spectrometry

Characterization workflow for fragments detected in capillary electrophoresis sodium dodecyl sulfate analysis of therapeutic monoclonal antibodies

Study of Monoclonal Antibody Aggregation at the Air-Liquid Interface under Flow by ATR-FTIR Spectroscopic Imaging

Charge Detection Mass Spectrometry Reveals Conformational Heterogeneity in Megadalton-Sized Monoclonal Antibody Aggregates

Effect of ionic strength and pH on the physical and chemical stability of a monoclonal antibody antigen-binding fragment.

Domain unfolding of monoclonal antibody fragments revealed by non-reducing SDS-PAGE

Stabilizing Two IgG1 Monoclonal Antibodies by Surfactants: Balance Between Aggregation Prevention and Structure Perturbation

Aggregation of therapeutic monoclonal antibodies due to thermal and air/liquid interfacial agitation stress: Occurrence, stability assessment strategies, aggregation mechanism, influencing factors, and ways to enhance stability

Characterization of monoclonal antibody size variants containing extra light chains

Hybrid mass spectrometry applied across the production of antibody biotherapeutics.

Intact NIST monoclonal antibody characterization—Proteoforms, glycoforms—Using CE-MS and CE-LIF

Size-exclusion Chromatography-Mass Spectrometry with M-Nitrobenzyl Alcohol As Post-Column Additive for Direct Characterization of Size Variants of Monoclonal Antibodies.

Unraveling the Microscopic Mechanism of Molecular Ion Interaction with Monoclonal Antibodies: Impact on Protein Aggregation

High Performance Size Exclusion Chromatography and High-Throughput Dynamic Light Scattering as Orthogonal Methods to Screen for Aggregation and Stability of Monoclonal Antibody Drug Products

Impact of NaCl on Monoclonal Antibody Aggregation Induced by Agitation

Physical origin of the peak tailing of monoclonal antibodies in size-exclusion chromatography using bio-compatible systems and columns

Comparative Analysis of Antibodies and Heavily Glycosylated Macromolecular Immune Complexes by Size-Exclusion Chromatography Multi-Angle Light Scattering, Native Charge Detection Mass Spectrometry, and Mass Photometry

Collision Induced Unfolding of Intact Antibodies: Rapid Characterization of Disulfide Bonding Patterns, Glycosylation, and Structures